Examining the role of specific genes in COVID-19 patients
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression In COVID-19 Patients: Impact of Ferretin and D -Dimer.
This study is testing how certain genes in the blood relate to the severity of COVID-19 in patients compared to healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Assiut) |
| Trial ID | NCT06080750 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of the NLRP3 inflammasome and IL-1β gene expression in COVID-19 patients by analyzing blood samples. It aims to compare the gene expression levels of these markers in COVID-19 patients against healthy individuals. Additionally, the study will explore the correlation between these inflammasome components and the severity of the disease, as well as the impact of ferritin and D-dimer levels on these biomarkers. The methodology includes quantitative real-time polymerase chain reaction (qRT-PCR) and ELISA techniques.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and over who have symptoms suggestive of COVID-19 and have tested positive via RT-PCR.
Not a fit: Patients under 18 years old or those with cancer may not benefit from this study due to the potential impact of their conditions on biomarker levels.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the inflammatory response in COVID-19, potentially leading to improved treatment strategies.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have explored the role of inflammatory markers in COVID-19 with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult Patient aged 18years and over presented to Assiut University Hospital * Suspected of covid19 because of the presence of symptoms suggestive of pneumonia (fever\>38) and at least one of the following symptoms ;cough, dyspnea, tachpnea or hypoxia * having RT-PCR (confirmed positive PCR) * Chest CT within 5 days of initial PCR Exclusion Criteria: * Cases less than 18 years old * Cancer patients (affect result of study as they have disrubted level of these biomarker)
Where this trial is running
Assiut
- Biochemistry department,Faculty of medicine — Assiut, Egypt (Recruiting)
Study contacts
- Study coordinator: Tasneem A Alsanory, Master
- Email: tasneem.a.alsanory@gmail.com
- Phone: +20106852153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.